See every side of every news story
Published loading...Updated

BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent Patients - Biomarin Pharmaceutical (NASDAQ:BMRN)

Summary by Benzinga
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released topline data from the Phase 3 PEGASUS trial evaluating Palynziq (pegvaliase-pqpz) compared to diet alone in 55 adolescents aged 12-17 with phenylketonuria (PKU). PKU is a rare, inherited metabolic disorder that prevents the body from breaking down the amino acid phenylalanine. Untreated phenylketonuria can lead to brain damage, intellectual disabilities, behavioral symptoms or seizures. The pri…

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

theweekenddrive.com broke the news in on Wednesday, April 2, 2025.
Sources are mostly out of (0)

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.